XiFin report: denials of lab claims up 40 percent in ’25
November 2026—Denials of clinical laboratory, molecular diagnostic, and genomics claims rose to 11.2 percent in 2025 from eight percent in 2024, a 40 percent jump that XiFin says erased two years of improvement, according to the company’s recently released 2026 Payor Denial Impact Report.
The report is based on an analysis of more than 30 million claims processed through XiFin’s Empower revenue cycle management solution, which the company says serves 11 of the 15 largest laboratories in the United States. It also provides segment-specific benchmarks across clinical laboratory, molecular, pathology, and hospital outreach providers.
“Health plans have modernized how they review claims. Decisions now happen in a fraction of a second with payors’ use of AI. Most health care providers haven’t, until now, had access to comparable AI-powered applications, and the numbers show it: more denials and more staff time to get paid for tests that were ordered and performed,” Kyle Fetter, XiFin chief operating officer, said in an Oct. 8 news release.
“Labs, molecular diagnostic providers, and pathology groups are absorbing that cost,” he said, “even as patients are picking up a larger share of a bill that too often started with a denial.”
Key findings of XiFin’s report:
- Denials rose across every insurer type, including traditional Medicare. Traditional Medicare had the lowest denial rate, at 3.4 percent of claims. Medicare Advantage and Medicaid managed care plans, along with other insurer groups, delivered significant increases in denial rates.
- Prior authorization denials for genetic and molecular tests more than doubled, to 27.6 percent of all denials, from 13.1 percent in 2021. Insurers have pledged to reduce prior authorization requirements, but denials have now shifted to “technical” and “payment integrity” categories, such as code mismatches and documentation deficiencies. The equivalent amount of denials now arrives under different denial codes.
- Procedure Not Paid Separately, a “bundling edit” in which the payer treats the test as already included in another paid service, is now the No. 1 reason clinical laboratory claims are denied. Payment rules that combine tests performed together into a single payment accounted for 59 percent of clinical lab denials, up from 33 percent in 2018. Bundling also accounted for more than 61 percent of hospital outreach laboratory denials, a segment the report analyzed separately for the first time.
- Patients are paying more, and providers are collecting less. The patient’s share of the bill rose to 30 percent in 2025 from 26 percent in 2023, while the portion of those balances collected fell to nine percent from 12 percent.
XiFin reported that a successful appeal in 2025 returned an average of $1,684 for molecular/genetic tests, $235 for pathology, $171 for clinical, and $48 for hospital outreach laboratories. But it says successful appeals often take two or three attempts, with each one taking a trained staff member 20 minutes or more to complete. With 84 percent of insurers using artificial intelligence in daily operations, an automated denial costs little to issue, XiFin says, while every appeal costs the provider real resources to respond.
The full report is available at https://bit.ly/Xifin-report.
Kitted NGS panel supports MRD detection in AML
Pillar Biosciences launched in October its MRDTect NPM1 and FLT3 ITD Panel, a research-use-only, kitted next-generation sequencing panel for measurable residual disease detection in acute myeloid leukemia.
As the company’s first MRD product, the panel detects NPM1 exon 12 mutations and FLT3 internal tandem duplications from a single genomic DNA input, down to 0.005 percent variant allele frequency. Pillar says the launch is its first step in helping laboratories localize NGS-based MRD testing.
The panel uses Pillar’s Stem-Loop Inhibition-Mediated amplification (SLIMamp) technology. Both targets are enriched in a simple, single-tube reaction and sequenced on standard 2 × 150 bp paired-end runs, with no long-read configuration required.
Pillar says the panel offers ultrahigh sensitivity and broad FLT3-ITD coverage with a simple, rapid workflow: single-tube library prep with about 3.5 hours of hands-on time, under 8.5 hours from DNA to sequencer, flexible stopping points, and sample-to-result in under 48 hours.
Informatics are integrated: PiVAT analysis software processes each sample in approximately three to 10 minutes through a user-friendly interface, with dedicated long-indel and FLT3-ITD calling and built-in QC metrics.
Low read requirements (≥1.2M paired-end reads for target VAF of 10-4; ≥8.9M paired-end reads for target VAF of 10-5) support cost-efficient, high-throughput, in-house testing.
WHO grants emergency use listing for Global Fever Special Pathogens Panel
The World Health Organization granted emergency use listing for the BioFire Global Fever Special Pathogens Panel, strengthening access to differential diagnostic testing in support of the Ebola Bundibugyo outbreak affecting the Democratic Republic of the Congo and neighboring countries.
The BioFire panel enables testing for 16 pathogens simultaneously from a single whole blood sample in about one hour, including multiple Ebola viruses, malaria parasites, and the Marburg, West Nile, and Lassa viruses.
The WHO emergency use listing serves as an international reference providing an additional accelerated pathway for health authorities, international organizations, and procurement partners to consider the panel as part of the response to the current outbreak and future preparedness efforts.
Qiagen and EQT reach deal
Qiagen and Swedish private equity firm EQT have agreed on an all-cash public takeover offer for all outstanding Qiagen shares at an offer price of 46.50 euros per share ($52.23). Qiagen said the price represents a 40.3 percent premium over its closing price on July 8.
The enterprise value of the deal is about $12.1 billion.
After the deal, which is expected to close in mid-2027, Qiagen is expected to operate under the same brand with its current management.
Myriad to sell Prenatal Health business to Labcorp
Myriad Genetics and Labcorp have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel, Foresight, SneakPeek, and FirstGene tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health testing business at closing.
Bryan Vaughn, Labcorp executive vice president and president of diagnostics, said in an Oct. 20 news release that the transaction supports Labcorp’s specialty testing growth strategy.
The deal is subject to regulatory clearance and customary closing conditions, and the transaction is expected to close by early 2027.
Draft LCD retired for biomarker testing in DCIS
Palmetto GBA and MolDX officially retired the draft local coverage determination for biomarker testing for risk stratification in DCIS. The retirement of L40142 was effective Oct. 8.
Palmetto GBA and collaborating Medicare administrative contractors cited “the numerous comments received related to current and impending clinical evidence to be considered” as the main reason for retiring the proposed coverage restriction.